Inovio’s Future Hinges on Critical Regulatory Submission

Inovio Pharmaceuticals shares edged higher in early trading, gaining 1.48% to reach $2.75. This modest uptick follows the company’s participation at the H.C. Wainwright Annual Global Investment Conference, where management is scheduled to deliver prepared presentations and conduct one-on-one meetings with potential investors.

Recent quarterly results released on August 12 reveal a strengthened financial position for the biotechnology firm. The company has demonstrated notable progress in several key areas:

• Net losses narrowed significantly to $23.5 million, compared to $32.2 million in the previous period
• Research and development expenditures were reduced by 30% to $14.5 million
• General and administrative costs decreased by 16% to $8.6 million

This improved financial discipline, combined with a July capital raise that generated approximately $22.5 million, Read more...